Cyltezo launches as first interchangeable Humira biosimilar

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.Six Humira biosimilars are set to launch in the United States in July, bringing the total number of available adalimumab biosimilar drugs to eight.Among the first of these July releases is Cyltezo (adalimumab-adbm, Boehringer Ingelheim), which has received FDA approval as an interchangeable biosimilar drug to adalimumab (AbbVie, Humira) and has been approvedRead More